We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-20.94%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$322M
AUM Growth
-$149M
Cap. Flow
-$24.6M
Cap. Flow %
-7.63%
Top 10 Hldgs %
58.84%
Holding
48
New
9
Increased
13
Reduced
15
Closed
3

Top Buys

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$8.17M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$3.9M
3
MRSN
Mersana Therapeutics
MRSN
+$3.32M
4
PRQR icon
ProQR Therapeutics
PRQR
+$3.31M
5
MASS icon
908 Devices
MASS
+$2.86M

Top Sells

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$20.7M
2
SMLR
Semler Scientific
SMLR
+$6.84M
3
CYTK icon
Cytokinetics
CYTK
+$6.16M
4
STRO icon
Sutro Biopharma
STRO
+$5.61M
5
BBIO icon
BridgeBio Pharma
BBIO
+$5.47M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$2.38B
$29.6M 9.18%
5,974,800
– –
CDXS icon
2
Codexis
CDXS
$182M
$27.7M 8.61%
1,345,000
– –
CMRX
3
DELISTED
Chimerix, Inc.
CMRX
$27M 8.4%
5,903,450
+323,450
+6% +$1.8M
HROW icon
4
Harrow
HROW
$1.44B
$22.4M 6.97%
3,291,343
+6,343
+0.2% +$49K
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$9B
$15.2M 4.72%
693,000
-31,400
-4% -$636K
CYTK icon
6
Cytokinetics
CYTK
$10.8B
$15M 4.65%
406,500
-173,500
-30% -$6.16M
KROS icon
7
Keros Therapeutics
KROS
$223M
$14.5M 4.49%
265,750
– –
TARA icon
8
Protara Therapeutics
TARA
$236M
$13.7M 4.24%
2,674,031
+24,031
+0.9% +$126K
RETA
9
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$13.3M 4.14%
407,002
+77,002
+23% +$2.28M
KNSA icon
10
Kiniksa Pharmaceuticals
KNSA
$6.23B
$11.1M 3.43%
1,112,500
+87,500
+9% +$927K
ETON icon
11
Eton Pharmaceutcials
ETON
$1.79B
$10.4M 3.22%
2,379,275
-5,725
-0.2% -$22.5K
MRUS
12
DELISTED
Merus
MRUS
$8.94M 2.78%
338,000
+20,200
+6% +$541K
STXS icon
13
Stereotaxis
STXS
$147M
$8.94M 2.78%
2,395,600
-130,900
-5% -$618K
TCON
14
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$8.3M 2.58%
157,755
+5,005
+3% +$252K
BCYC
15
Bicycle Therapeutics
BCYC
$303M
$7.68M 2.38%
+175,000
New +$8.17M
XOMA
16
DELISTED
Xoma
XOMA
$7.58M 2.36%
271,000
-67,350
-20% -$1.54M
CLDX icon
17
Celldex Therapeutics
CLDX
$3.18B
$6.66M 2.07%
195,500
-648,500
-77% -$20.7M
PTGX icon
18
Protagonist Therapeutics
PTGX
$9.67B
$5.96M 1.85%
251,500
-90,500
-26% -$2.55M
TELA icon
19
TELA Bio
TELA
$29.2M
$5.55M 1.72%
477,000
+27,133
+6% +$328K
FBIO icon
20
Fortress Biotech
FBIO
$93.4M
$5.1M 1.58%
250,000
– –
PCVX icon
21
Vaxcyte
PCVX
$9.1B
$5.1M 1.58%
211,000
-104,800
-33% -$2.29M
FDMT icon
22
4D Molecular Therapeutics
FDMT
$824M
$4.91M 1.53%
325,000
+96,000
+42% +$1.51M
LRMR icon
23
Larimar Therapeutics
LRMR
$421M
$3.82M 1.19%
943,702
+60,100
+7% +$393K
DNA icon
24
Ginkgo Bioworks
DNA
$489M
$3.75M 1.16%
23,245
– –
SMLR
25
DELISTED
Semler Scientific
SMLR
$3.47M 1.08%
70,000
-102,000
-59% -$6.84M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2022 Portfolio in Review

As of Q1 2022, Opaleye Management held 48 positions worth $322M, down 32% from $471M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management withdrew a net $24.6M in Q1 2022, closing 3 positions and reducing 15 holdings. Its most notable exit was BridgeBio Pharma, an estimated $5.47M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Opaleye Management opened a new position in Bicycle Therapeutics worth $7.68M.

  • Opaleye Management's largest Q1 2022 buy was Bicycle Therapeutics: 175,000 shares worth $7.68M.
  • Opaleye Management added most to ProQR Therapeutics in Q1 2022, an estimated $3.31M increase.
  • Opaleye Management's biggest Q1 2022 reduction was Celldex Therapeutics, cutting an estimated $20.7M.
  • Opaleye Management fully exited BridgeBio Pharma in Q1 2022, selling an estimated $5.47M.
  • Opaleye Management's ten largest holdings make up 59% of its $322M portfolio in Q1 2022.
  • Opaleye Management opened 9 new positions and closed 3 in Q1 2022.
  • Opaleye Management's portfolio value fell 32% quarter-over-quarter to $322M.

Based on Opaleye Management's 13F filing for Q1 2022, filed 16 May 2022.